Finance

Lists
A1ZN34:BVMF
Astrazeneca Plc Bdr
139,90 BRL
0,00%
(0,00) 1D
16-окт., 17:06:00 GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for A1ZN34...
Open
143,33 BRL
High
143,33 BRL
Low
138,81 BRL
Mkt. cap
259,42 млд
Avg. vol.
892,00
Volume
1,25 миң
52-wk high
190,40 BRL
52-wk low
129,06 BRL
Shares outstanding
1,55 млд
No. of employees
96 миң
Open
143,33 BRL
High
143,33 BRL
Low
138,81 BRL
Mkt. cap
259,42 млд
Avg. vol.
892,00
Volume
1,25 миң
52-wk high
190,40 BRL
52-wk low
129,06 BRL
Shares outstanding
1,55 млд
No. of employees
96 миң
News stories
From web sources and news partners
Profile
AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, England; Gothenburg, Sweden; and Gaithersburg, Maryland, US. AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Wikipedia
About Astrazeneca Plc Bdr
CEOPascal Soriot
Employees96,1 миң
Founded1999-ж., 6-апр.
HeadquartersКембридж, Кэмбриджшир, Улуу Британия
SectorPharmaceutical industry
Next call 12 күндөн кийин
30-окт., жума, 16:30
Fiscal period
Q3 2026
- / 2,57 USD
Revenue / Est. (USD)
- / 15,99 млд
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
15,19 млд
15,50 млд
15,29 млд
15,38 млд
Cost of goods sold
2,79 млд
3,17 млд
2,67 млд
2,53 млд
Cost of revenue
2,79 млд
3,17 млд
2,67 млд
2,53 млд
Research and development expenses
3,63 млд
3,62 млд
3,47 млд
3,67 млд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5,20 млд
5,32 млд
5,03 млд
5,72 млд
Operating expense
8,74 млд
8,99 млд
8,34 млд
9,24 млд
Total operating expenses
11,53 млд
12,16 млд
11,02 млд
11,78 млд
Operating income
3,66 млд
3,35 млд
4,27 млд
3,61 млд
Other non operating income
-
-247,00 млн
-
-
EBT including unusual items
3,24 млд
2,63 млд
3,91 млд
2,80 млд
EBT excluding unusual items
3,32 млд
3,05 млд
3,94 млд
3,24 млд
Income tax expense
709,00 млн
300,00 млн
833,00 млн
291,00 млн
Effective tax rate
21,86%
11,41%
21,28%
10,40%
Other operating expenses
-89,00 млн
53,00 млн
-155,00 млн
-152,00 млн
Net income
2,53 млд
2,33 млд
3,08 млд
2,51 млд
Net profit margin
16,67%
15,00%
20,15%
16,30%
Earnings per share
2,38
2,12
1,29
2,63
Interest and investment income
85,00 млн
135,00 млн
73,00 млн
80,00 млн
Interest expense
-434,00 млн
-155,00 млн
-393,00 млн
-435,00 млн
Net interest expenses
-349,00 млн
-20,00 млн
-320,00 млн
-355,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
5,21 млд
4,11 млд
5,64 млд
5,19 млд
Gain or loss from assets sale
-31,00 млн
-37,00 млн
-34,00 млн
-94,00 млн
AI content may include mistakes. Learn more
Google колдонмолору